Categories
Press Release

Joint Pain Injections Market by Size, Share & Geographical Overview till 2026

CDC reports that every year approximately 15 million people in the U.S. face severe joint pain because of arthritis. The rising prevalence of arthritis can increase the demand for treatments, which in turn, will propel the growth of the global joint pain injections market. The information is shared by Fortune Business Insights, in a report, titled “Joint Pain Injections Market Size, Share and Global Trend By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma Injections, Others (Placental Tissue Matrix Injections, etc), By Joint Type (Knee and Ankle, Hip, Shoulder and Elbow, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.”

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/joint-pain-injections-market-100871

Some of the other players functioning in the global market are

Joint Pain Injections Market
Joint Pain Injections Market
  • Anika Therapeutics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Flexion Therapeutics Inc.
  • Pfizer Inc.
  • Reddy’s Laboratories Ltd.
  • Zimmer Biomet
  • Bioventus
  • SEIKAGAKU CORPORATION,
  • ALLERGAN, and Ferring B.V.

One of the most common types of arthritis is osteoarthritis which primarily affects hands and feet. Some of the major causes associated with osteoarthritis are the rising prevalence of obesity, increasing aging population, zero physical activity, and mineral bone density loss.  Injections such as hyaluronic acid and corticosteroid are extensively used to reduce pain and inflammation in affected areas.

Joint pains are more prevalent in the elderly population. As per research studies, injections such as platelet-rich plasma and placental tissue matrix have proved to be effective in the reduction of pain and inflammation. Furthermore, these infections will substantially reduce the risk of infection on the affected joint in the aged population. Driven by such factors, the joint pain injections market growth is likely to increase in the forthcoming years.

Surging Research Investments to Give Significant Boost to the Market in North America

According to Arthritis Foundation, around 54 million people in the people suffer from arthritis and it is estimated that over 78 million people will be affected by this disease by 2040. This shows that the demand for joint pain medicine is likely to increase in the U.S., which drives the market in North America. As per the report, North America is anticipated to maintain its dominance in the global joint pain infections market through the forecast years. The growth is primarily attributable to the increasing prevalence of joint disorders. People in this region are increasingly becoming aware of joint pain infections treatment. Not only this, leading players are making huge investments in research activities, which will eventually drive the market in North America. Several treatments such as knee arthritis viscosis supplementation received FDA approval, which contributes to the growth of the market in this region. Following North America, Europe is also expected to grow at a considerable rate in the forecast period.

Get Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/joint-pain-injections-market-100871

The market in Asia Pacific is expected to witness considerable growth owing to the rising prevalence of joint disorders and patient pool. Several government organizations are conducting awareness programs on different types of arthritis treatments available in the region. This will enhance the quality of life for such patients and augment demand for joint pain injections. Influenced by these factors, the joint pain infections market size is estimated to grow over the projected horizon.

Segmentation for Joint Pain Injections Market

By Product

  • Corticosteroid Injections
  • Hyaluronic Acid Injections
  • Platelet-Rich Plasma Injections
  • Others (Placental Tissue Matrix Injections, etc.)

By Joint Type

  • Knee and Ankle
  • Hip
  • Shoulder and Elbow
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

SYNOJOYNT Receives FDA Approval to Teva Pharmaceuticals for Treating Osteoarthritis Patients

Joint pain injections are available for different joints which include hip, knee and ankle, shoulder and elbow. Of these, knee and ankle joints hold the largest share in the global market. This will surge the joint pain injections market size in the forthcoming years. These injections effectively reduce inflammation and pain in knees, thus increasing their demand.

“The demand for cost-effective treatments is increasing and the rising prevalence of osteoarthritis are driving the joint pain injections market,” stated a lead analyst at Fortune Business Insights. These, coupled with rising technological advancements in healthcare, are likely to uplift the market growth. Several companies are introducing new products to strengthen their market position. SYNOJOYNT, a joint pain injection receives FDA approval on marketing this product. The injection was introduced by TEVA Pharmaceuticals in May 2018 for patients suffering from osteoarthritis. Zimmer Biomet develops a new joint pain injection containing hydraulic acid called Gel-One Hyaluronate. The injection received FDA approval in February 2017 and is used to treat patients with knee osteoarthritis.

Speak To Analyst at https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/joint-pain-injections-market-100871

STRONG INDUSTRY FOCUS:

  • Extensive product offerings
  • Customer research services
  • Robust research methodology
  • Comprehensive reports
  • Latest technological developments
  • Value chain analysis
  • Potential market opportunities
  • Growth dynamics
  • Quality assurance
  • Post-sales support
  • Regular report updates

View Related Report at

Cocoa and Chocolate Market 2019: Global Industry Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast to 2025

Cocoa and Chocolate Market Research Reports 2019 | Global Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Categories
Press Release

Savory Ingredients Market Projected Industry Growth, Regional Industry Share to 2026

The Global Savory Ingredients Market will expand at a considerable pace of 6.65% CAGR between 2019 and 2026. In the coming years, it is likely to gain impetus from the growing demand for new flavors and the ability of savory ingredients to suffice these needs. According to a report published by Fortune Business Insights, titled “Savory Ingredients: Global Market Analysis, Insights, And Forecast, 2019-2026,” the market was valued at US$ 7.25 Bn in 2018. Fortune Business Insights states that the market will reach US$ 11.94 Bn by 2026.

Browse Complete Report Details @

https://www.fortunebusinessinsights.com/industry-reports/savory-ingredients-market-100256

Symrise’s Launch of Clean Labelled Culinary Base Products Will Enable Market Growth

The demand for clean labeled products has resulted from increasing health awareness across the world. In the wake of an outcry for clean-labeled products, many companies are adapting to this strategy. This factor will help the company acquire a strong consumer base, which in turn will favor the growth of the global savory ingredients market.

In 2018, Symrise Flavor N.A. introduced an extensive line of culinary base ingredients with clean-labelled packaging. The company stated that its latest collection includes a wide range of vegetables and spices, thereby pertaining to a widespread audience. Fortune Business Insights states that the launch of products within the clean-label regulatory framework will aid the growth of the global savory ingredients market.

Get Sample PDF [email protected]

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/savory-ingredients-market-100256

Some of the Main Key Players Covered in the Report

  • Ajinomoto Co., Inc.
  • Koninklijke DSM N.V.
  • Kerry Group PLC
  • Tate & Lyle PLC
  • Symrise AG
  • Givaudan SA
  • Sensient Technologies Corporation
  • Savoury Systems International LLC
  • P. Ingredients Ltd.
  • Synergy Flavors

Key Segmentation:

By Type

  • Starches
  • Proteins
  • Yeast
  • MSG (Monosodium Glucamate)

By Form

  • Powder
  • Liquid
  • Paste

By End Use

  • Food Processors
  • Food Services (HoReCa)

By Source

  • Natural
  • Synthetic

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Kerry Group’s Dual Acquisition Will Boost the Global Market

The demand for savory ingredients has risen significantly in recent years due to changing lifestyle dietary habits. The savory ingredients are being used for the manufacture of healthy foods as well as vegan-based diets, to enhance the overall taste of the food products. Resulting from the soaring demand, companies are engaged in attractive business strategies and are conducting mergers and acquisitions, company collaborations, and agreements.

In December 2018, Kerry Group announced that it plans to acquire two renowned food companies for a combined total of over US$ 300 Mn. Kerry Group’s plans to acquire Ariake Japan Co. and Southeastern Mills (SEM), with an aim of expanding its clean-label product distribution to several countries across the world.

The report identifies a few of the leading company mergers and acquisitions that have accounted for the growth of the global savory ingredients market. Besides mergers and acquisitions, the report includes several factors that have made growth contributions to the global market.

More Trending Topics from Fortune Business Insights:

Cardiovascular Stents Market 2019 Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2025

Coronary Stents Market 2019 Size, Revenue, Share and Global Trend By Deployment, Stent Type, End User and Geography Forecast till 2025

Categories
Press Release

Next-Generation Sequencing Market 2019 Research Report, Trends, Growth Rate, Scope Forecast 2026

The Global Next-Generation Sequencing Market is forecast to exhibit a remarkable CAGR as the next-generation sequencing platform allows effective sequencing of millions of DNA molecules. Fortune Business Insights in a new report, titled “Next-Generation Sequencing: Global Market Analysis, Insights and Forecast, 2019-2026” offers a detailed analysis of the competitive landscape and market dynamics.

Browse Complete Report Details @

https://www.fortunebusinessinsights.com/industry-reports/next-generation-sequencing-ngs-market-101000

As per the report, the global market is expected to rise at a ferocious CAGR of 22.2% between 2018 and 2026. In 2018, the market was worth US$ 6,335.2 Mn and the market will be a howling success as it is projected to reach US$ 31,411.3 Mn by 2026.  The demand for next-generation sequencing methodologies is increasing rapidly across several applications such as diagnostics, clinical research among others.

Adapative Technologies developed a next-generation sequencing diagnostic test called ClonoSEQ for patients suffering from acute lymphoblastic leukemia or ALL and minimal residual disease or MRD. The test received FDA approval in September 2018, which in turn, contributes to the growth of the market in North America.

Get Sample PDF [email protected]

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/next-generation-sequencing-ngs-market-101000

Some of the Main Key Players Covered in the Report:

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • QIAGEN
  • BGI
  • PerkinElmer Inc.
  • Eurofins Scientific
  • Macrogen, Inc.
  • PierianDx

Key segmentation:

By Type

  • Products
  • Instruments & Software
  • Consumables
  • Services

By Application

  • Diagnostics
  • Research

By End User

  • Research Institutes
  • Healthcare Facilities & Diagnostic Centers
  • Pharmaceutical & Biotechnological Companies
  • Contract Research Organization (CROs)

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

SECONDARY DATA SOURCES THAT WE REFER TO:

  • Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
  • Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
  • Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
  • Industry journals and paid databases

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.

More Trending Topics from Fortune Business Insights:

Vitiligo Treatment Market Growth 2019| Worldwide Opportunities, Market Share, Key Players and Competitive Landscape

Corn Starch Market 2019 Global Industry Size, Segments, Applications and Growth Factor Analysis Research Report 2026

Categories
Press Release

Glaucoma Therapeutics Market Size, by Key Players | Industry Forecast by Categories, Platform, End – User

According to the report Glaucoma Therapeutics Market in North America was worth US$ 2405.9 Mn in 2018. The region is expected to dominate the global market during the forecast period 2019-2026. The growth predicted in North America is attribute to its constantly improving healthcare facilities and adoption of recent advances in glaucoma diagnosis, treatment, and medication. These factors also are expected to bode well for the global glaucoma therapeutics market. Meanwhile, the increasing number of glaucoma cases in nations such as China and India is projected to enable growth in Asia Pacific. Additionally, the region is anticipated to progress at a relatively high CAGR.

Key Segmentation

By Drug Class

  • Beta Blockers
  • Prostaglandins
  • Latanoprost
  • Bimatoprost
  • Travoprost
  • Others
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

By Disease Indication

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/glaucoma-therapeutics-market-100312

Prostaglandins to Remain Dominant among Drug Class Through Forecast Period

In terms of drug class, prostaglandins are the most widely used medication. Additionally, in 2018 the prostaglandins segment was dominating the global glaucoma therapeutics market. The segment accounted for 40.2% of the global market in 2018. Prostaglandins are forecast to dominate the global market during the forecast period as well. Higher efficiency to reduce intraocular pressure (IOP) and minimal risk of side effects associated with the drugs are a few factors aiding the expansion of the prostaglandins segment.

Allergan and Novartis AG, Together Leading the Global Market Since 2018

The global glaucoma therapeutics market is witnessing an influx of new players. Allergan and Novartis AG, are currently leading players in the global market. The companies are involved in manufacturing and marketing of prostaglandin analogues. Among, prostaglandin analogues Lumigan and Travatan are the two most preferred medications for the treatment of glaucoma. Quality production and marketing of these drugs have enabled the organizations establish a stronghold in the global market. Besides this, other companies operating in the market are Pfizer, Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Teva Pharmaceutical Industry, Aerie Pharmaceuticals, Pfizer, Inc., and Inotek Pharmaceuticals.

Its All About Building Intelligent Machines to Simplify Complex Tasks: Introducing Surgical Robots

Top Player:

  • include Pfizer, Inc.,
  • Merck & Co., Inc.,
  • Bausch & Lomb Incorporated,
  • Teva Pharmaceutical Industry,
  • Aerie Pharmaceuticals,
  • Pfizer, Inc.,
  • Inotek Pharmaceuticals.

In December 2017, Aerie Pharmaceuticals Inc. introduced new eye drops called Rhopressa. The eye drop is specially designed for faster treatment of glaucoma. This may also positively impact the organization’s current position in the market and enable it gain higher share in the global glaucoma therapeutics market.

Secondary Research Is Conducted To Derive The Following Information

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.

More Trending Topics From Fortune Business [email protected] 

Veterinary Therapeutics Market , Share, Growth, Opportunities and Forecast to 2025

Veterinary Drugs Market 2019 Global Industry Share, Size, Top Leading Players

Categories
Press Release

Global Surgical Robots Market was Valued at US$ 6,875.1 Mn: Fortune Business Insights

The Global Surgical Robots Market was valued at US$ 1,463.0 Mn in 2018. Fortune Business Insights predicts that the market will reach 6,875.1 Mn by 2026, thereby exhibiting a CAGR of 21.4% during the forecast period.

The need for zero or minimum margin of error has opened the doors for innovations and created a potential for growth of the global surgical robots market, through the development of highly efficient products. Furthermore, surgical robots help surgeons operate with the utmost stability and enhanced movements while dealing with neurological parts of the body, which in turn minimizes damage of healthy tissues. The aforementioned factors will contribute to an increase in the global surgical robots market value and will help the market grow at a considerable rate in the forthcoming years.

Segmentation

By Application

  • General Surgery
  • Gynecology
  • Urology
  • Orthopedics
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

By Geography

  • North America (the USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Rest of World

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/surgical-robots-market-100948

Key questions answered in the Surgical Robots Market report:

What will the market growth rate of Surgical Robots market in 2026?

What are the key factors driving the Global Surgical Robots market?

What are sales, revenue, and price analysis of top manufacturers of Surgical Robots market?

Its All About Building Intelligent Machines to Simplify Complex Tasks: Introducing Surgical Robots

Rising Regulatory Approvals Identified as Chief Growth Driver

As surgical robots are essentially dealing with sensitive parts of the body, regulatory authorities are somewhat reluctant to clear the products for usage. Having said that, recent advancements in surgical robots and the advent of high precision products have churned out several regulatory clearances. Subsequently, increasing regulatory approvals will favor the growth of the global surgical robots market.

More Trending Topics From Fortune Business [email protected]

Contraceptives Market to reach US$ 31,666.9 Mn by 2025, Recent Approvals from Medicines and Healthcare Regulatory Agency (MHRA) to Impel Growth, says Fortune Business Insights

Digital Blood Pressure Monitor Market to Exhibit 10.1% CAGR, Omron to Leading the Market with its Large Distribution Network, says Fortune Business Insights

Categories
Press Release

Global Genomics Market Trends, Demand, Growth Opportunity, Regional Outlook, & Forecast 2018-2026

Genomics Market is most commonly used for the diagnosis of cancer. Recent advancements in personalized medicine and genomics have bought significant transformations in disease management. The growing use of genomics in several clinical trials is reflecting a growing trend. Consequently, The Global Genomics Market is expected to rise at an exponential CAGR of 18.7% between 2018 and 2026. In 2018, the market was valued at US$ 15,888.8 Mn and it is anticipated to reach US$ 62,614.6 Mn by 2026.

Adoption of Advanced Technologies Renders North America Dominant

From a geographical standpoint, North America dominated the global genomics market in 2018. The region will continue to maintain its dominance through the forecast period. Rapid technological advancements and the presence of sophisticated healthcare infrastructure are driving the market in this region. In 2018, North America was valued at US$ 6,959.3 Mn. The demand for genomic medicine is increasing in North America on account of the rising adoption of personalized medicine and new sequencing technologies.

Segmentation

By Product Type

  • Reagents
  • Kits
  • Enzymes
  • Others

By Technology

  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • MicroRNA Modification
  • Large Non-coding RNA
  • Chromatin Structures
  • Others

By Application

  • Pharmaceutical
  • Diagnostics

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941

Veritas Genetics Launched myGenome to Offer Personalized Services to its Customers

General Electric Company, Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., IntegraGen, QIAGEN, BGI, F. Hoffmann-La Roche Ltd, Danaher, and Illumina, Inc. are some of the leading players in the global genomics market. Among these, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., and Illumina, Inc. are projected to dominate the global market. Strong geographical presence and robust portfolio are factors responsible for their prominent position in the market.

A Myriad of R&D Activities Has Spurred Growth Prospects for Genomics Market

“Several services and start-up companies are paving their way into genomics industry by offering services which include ancestry services, direct-to-customer genomic services, among others,” stated a lead analyst at Fortune Business Insights. “Rising support from governments regarding research and funding is expected to contribute to the growth of the market,” he added. Several genomic institutes are supporting the industry by granting funds for performing research and development activities. Stanford healthcare uses genomic information to develop a personalized treatment for patients suffering from chronic illness.

Secondary Data Sources That We Refer To

  • Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
  • Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
  • Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
  • Industry journals and paid databases

Its All About Building Intelligent Machines to Simplify Complex Tasks: Introducing Surgical Robots

The lower costs of genetic procedures is likely to contribute to the development of the genomic market in the forthcoming years. Technological advancements in genomic medicine which include Next-generation Sequencing (NGS), Sanger sequencing, Polymerase Chain Reactions (PCR), and microarray are likely to drive the market. Of these, Polymerase Chain Reactions (PCR) covered the maximum share in the global market in 2018. The easy availability and extensive use of this technology are responsible for this segment’s growth. Owing to the increasing number of genetic studies, the demand for genomics is expected to fuel in healthcare facilities & diagnostic centers, Contract Research Organization (CROs) and others.

More Trending Topics From Fortune Business [email protected]

Biopesticides Market to reach US$ 10.19 Billion by 2025, at a CAGR of 14.93% | Exclusive Report by Fortune Business Insights

Crop Protection Chemicals Market to Reach US$ 68.82 Bn by 2025, Relaxation in Usage Guidelines to Boost the Market, says Fortune Business Insights

Categories
Press Release

U.S. Biosimilars Market to Worth US$ 17,696.0 Mn by 2026; Rise in Research and Development Activities to Boost the Market

The U.S. Biosimilars Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018. titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The U.S. Biosimilars Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market.

Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.

The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment.

The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040. This in turn, will increase the demand for biosimilars to treat arthritis. Moreover, treatment of cancer is expensive in the U.S. Combined with this, constant investments in research and development and rise in the adoption of sedentary lifestyle are projected to favor growth of the cancer segment throughout the forecast period in the U.S.

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990

Table of content:

  1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

  1. Executive Summary
  2. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

  1. Key Insights

4.1 Prevalence of Key Disease Associated with the Scope – U.S., 2018

4.2 New Product Launch

4.3 Pipeline Analysis

4.4 Regulatory Scenario

4.5. Reimbursement Scenario

4.6. Patent Snapshot of Biologics

4.6 Key Industry Developments – Partnerships, Mergers & Acquisitions

  1. U.S. Biosimilars Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Drug Class

5.2.1 Filgrastim & Pegfilgrastim

5.2.2 Monoclonal Antibodies

5.2.2 Others

5.3. Market Analysis, Insights and Forecast – By Disease Indication

5.3.1 Cancer

5.3.2 Autoimmune Diseases

5.3.2.1 Arthritis

5.3.2.2 Psoriasis

5.3.2.3 Neutropenia

5.3.2.4 Others

5.3.3 Others

5.4. Market Analysis, Insights and Forecast – By Distribution Channel

5.4.1 Hospital Pharmacy

5.4.2 Retail Pharmacy

5.4.3 Online Pharmacy

…………….

Its All About Building Intelligent Machines to Simplify Complex Tasks: Introducing Surgical Robots

Segmentation

By Drug Class

  • Filgrastim & Pegfilgrastim
  • Monoclonal Antibodies
  • Others

By Disease Indication

  • Cancer
  • Autoimmune Diseases
  • Arthritis
  • Psoriasis
  • Neutropenia
  • Others
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.

Pfizer Inc., Samsung Bioepis Co. Ltd., and Other Key Players Tend to Focus on Product Launch to Strengthen Position

Samsung Bioepis Co. Ltd, a biopharmaceutical company, received approval from Food and Drugs Administrations for ETICOVO, a biosimilar of Etanercept in April 2019. It is used for the treatment of plaque psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis. Pfizer Inc. a multinational pharmaceutical company based in the U.S., received approval from FDA for TRAZIMERA, a biosimilar referencing Herceptin in March 2019. It will be used to treat gastroesophageal junction adenocarcinoma and breast cancer. Earlier in July 2018, Pfizer Inc. announced that the company has received FDA approval for NIVESTYM. It is a biosimilar to Neupogen that is approved to treat neutropenia. The FDA also granted approval for Truxima, the first biosimilar of rituximab in November 2018. It is developed by Celltrion Inc., a biopharmaceutical company headquartered in South Korea, for the treatment of non-Hodgkin’s lymphoma.

Secondary Research Is Conducted To Derive The Following Information

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.

More Trending Topics From Fortune Business [email protected]

Medical Devices Market to Value US$ 602.1 Bn at CAGR of 5.3% by 2025 | Exclusive Report by Fortune Business Insights

Peritoneal Dialysis Market to Reach US$ 6,077.2 Mn by 2025, with a CAGR of 6.9% | Exclusive Report by Fortune Business Insights